# US 2005/0032791 A1 · Derivatives of sulphonamides, their preparation and use as medicaments

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0032791 A1
- Document ID: US20050032791A1
- Status: Published application
- Kind: A1
- Application number: 10/933,951
- Filed: 2004-09-03
- Published: 2005-02-10
- Earliest claimed: 2001-11-17
- Assignees: Laboratories Del Dr. Esteve, S.A.
- Inventors: Ramon Merc-Vidal; Blas Andaluz-Mataro; Jordi Frigola-Constansa
- Web page: https://patentgrep.com/patent/US20050032791A1

## CPC

- C04B 35/632: Organic additives
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 209/14: Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D 209/16: Tryptamines
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 409/14: containing three or more hetero rings
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 513/04: Ortho-condensed systems
- C04B: LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE {(roofing granules E04D7/005)}; CERAMICS (devitrified glass-ceramics C03C10/00); REFRACTORIES; TREATMENT OF NATURAL STONE
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to new derivatives of sulphonamides, with the general formula (I), as well as to their physiologically acceptable salts, the processes for their preparation, their application as medicaments in human and/or veterinary therapy and the pharmaceutical compositions that contain them.

## Claims

### Claim 1

A compound derived of sulphonamide with the general formula
wherein
a represents a substituent selected from among:
A bicyclic heteroaromatic ring containing 1 to 3 heteroatoms selected from among oxygen, nitrogen and sulphur, optionally substituted by 1 or 2 halogen atoms or by a C1-C4 alkyl radical; p1 A group selected from among:
R1 represents hydrogen, a C1-C4 alkyl radical or a benzyl radical;
n represents 0, 1, 2, 3 or 4;
R2 represents —NR4R5 or a group with formula:
Wherein the dotted line represents an optional chemical bond; and
R3, R4 and R5 independently represent hydrogen or a C1-C4 alkyl;
X, Y and Z independently represent hydrogen, fluorine, chlorine, bromine, a C1-C4 alkyl, a C1-C4, alkoxy, a C1-C4 alkylthio, trifluoromethyl, cyano, nitro and —NR4R5
W represents a bond between the two rings, CH2, O, S and NR4;
m represents 0, 1, 2, 3 or 4;
with the condition that when m=0, A is a substituted phenyl; or one of its physiologically acceptable salts.

### Claim 2

(Cancelled)

### Claim 3 (depends on 1)

Process for preparing a derivative of sulphonamide with the general formula (I), according to claim 1, characterized by making react a compound with the general formula (II), or one of its suitably protected derivatives,
wherein A is as indicated previously in the general formula (I), in claim 1, and X is an suitable salient group including an halogen atom, particularly chlorine:
with a 5-aminoindol with the general formula (III), or one of its suitably protected derivatives;
wherein n, R1, R2 and R3 are as indicated above in the general formula (I), in claim 1; in order to obtain the corresponding sulphonamide, and optionally it is possible to eliminate eventually the protective groups from it.

### Claim 4 (depends on 1)

Process for preparing a derivative of sulphonamide with the general formula (I), according to claim 1 wherein R1, R2, R4, n and A are as indicated above in claim 1, and R3 represents a C1-C4 alkyl characterized by making react a compound with the general formula (I). wherein R, R2, R4, n and A are as indicated above in claim 1, and R3 represents an atom of hydrogen, with an alkyl halogenide or dialkyl sulphate.

### Claim 5 (depends on 1)

Process for preparing a derivative of sulphonamide with the general formula (I), according to claim 1, wherein R1, R3, and A are as indicated above in claim 1, n=0 and R2 represents a 1,2,3,6-tetrahydropyridin-4-yl radical substituted in position 1 with an R1 radical, characterized by making react a compound with the general formula (I), wherein R1, R3, and A are as indicated above in claim 1, n=0 and R2 represents an atom of hydrogen with a 4-piperidone substituted in position 1 with an R1 radical.

### Claim 6 (depends on 1)

Process for preparing a derivative of sulphonamide with the general formula (I), according to claim 1, wherein R1, R3, and A are as indicated above in claim 1, n=0 and R2 represents a 4-piperidinyl radical substituted in position 1 with an R1 radical, by reduction of a compound with the general formula (I) wherein R1, R3, and A are as indicated above in claim 1, n=0 and R2 represents a 1,2,3,6-tetrahydropyridin-4-yl radical substituted in position 1 with an R1 radical.

### Claim 7 (depends on 1)

Process for preparation of physiologically acceptable salts of the compounds with the general formula (I), according to claim 1, consisting in making react a compound with the general formula (I) with a mineral acid or an organic acid in a suitable solvent.

### Claim 8 (depends on 1)

Pharmaceutical compositions, characterized in that they contain, in addition to the pharmaceutically acceptable excipients, at least one compound with the general formula (I) or one of its physiologically acceptable salts, according to claims 1.

### Claim 9 (depends on 1)

A method of preventing or treating anxiety, depression, cognitive memory disorders and senile dementia processes and other dementias where a cognition deficit is predominant, psychosis, infant hyperkinesias (ADHD, attention deficit/hyperactivity disorder) and other disorders mediated by the 5HT6 receptor of serotonin in mammals, including man comprising administering a therapeutically effective amount of a compound according to claim 1 to a mammal in need thereof.

### Claim 10

A pharmaceutical composition comprising a compound derived of sulphonamide with the general formula (1)
wherein
A represents a substituent selected from among:
A heteroaromatic ring of 5 or 6 members containing 1 or 2 heteroatoms selected from among oxygen, nitrogen and sulphur, optionally substituted by 1 or 2 halogen atoms. by a C1-C4 alkyl radical or by a phenyl or heteroaryl radical with 5 or 6 members containing 1 or 2 atoms of oxygen, nitrogen or sulphur;
A bicyclic heteroaromatic ring containing 1 to 3 heteroatoms selected from among oxygen, nitrogen and sulphur, optionally substituted by 1 or 2 halogen atoms or by a C1-C4 alkyl radical;
A group selected from among:
R1 represents hydrogen, a C1-C4 alkyl radical or a benzyl radical;
n represents 0, 1, 2, 3 or 4;
R2 represents —NR4R5 or a group with formula:
Wherein the dotted line represents an optional chemical bond; and
R3, R4 and R5 independently represent hydrogen or a C1-C4 alkyl; p1 X, Y and Z independently represent hydrogen, fluorine, chlorine, bromine, a C1-C4 alkyl, a C1-C4, alkoxy, a C1-C4 alkylthio, trifluoromethyl, cyano, nitro and —NR4R5
W represents a bond between the two rings, CH2, O, S and NR4;
m represents 0, 1, 2, 3 or 4;
with the condition that when m=0, A is a substituted phenyl; or one of its physiologically acceptable salts.

### Claim 11 (depends on 1)

A compound according to claim 1 wherein A represents a heteroaromatic ring of 5 or 6 members containing 1 or 2 heteroatoms selected from among oxygen, nitrogen and sulfur, optionally substituted by 1 or 2 halogen atoms, by a C1-C4 alkyl radical or by a phenyl or heteroaryl radical with 6 or 6 members containing 1 or 2 atoms of oxygen, nitrogen or sulfur.

### Claim 12 (depends on 1)

A compound according to claim 1 wherein A represents a bicyclic heteroaromatic ring containing 1 to 3 heteroatoms selected from among oxygen, nitrogen and sulfur, optionally substituted by 1 or 2 halogen atoms or by a C1-C4 alkyl radical.

### Claim 13 (depends on 1)

A compound according to claim 1 wherein A represents a compound selected from among:

### Claim 14 (depends on 10)

A method of treating or preventing anxiety, depression, cognitive memory disorders and senile dementia processes and other dementias where a cognition deficit is predominant, psychosis, infant hyperkinesias (ADHD, attention deficit/hyperactivity disorder) and other disorders mediated by the 5HT6 receptor of serotonin in mammals, including man, comprising administering an effective amount of the medicament of claim 10 to a mammal in need thereof.
